Amphastar Pharma (AMPH) Tops Q2 EPS by 9c

Amphastar Pharma (NASDAQ: AMPH) reported Q2 EPS of $0.65, $0.09 better than the analyst estimate of $0.56. Revenue for the quarter came in at $145.7 million versus the consensus estimate of $137.37 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Carvana (CVNA) PT Lowered to $85 at RBC Capital
• Aspire Biopharma to acquire automotive supplier for $30 million